Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population.

Publication Type:

Journal Article


AIDS patient care and STDs, Volume 23, Issue 11, p.925-9 (2009)


2009, Adult, Anti-HIV Agents, Antiviral Agents, Cohort Studies, Drug Therapy, Combination, Female, Hepacivirus, Hepatitis C, HIV Infections, HIV-1, Humans, Male, Middle Aged, Outpatient Clinics, Hospital, Proportional Hazards Models, Retrospective Studies, Survival Analysis, Time Factors, Urban Population, Vaccine and Infectious Disease Institute, Young Adult


This retrospective cohort study of HIV/hepatitis C virus (HCV) coinfected patients evaluated time trends and rates of HCV evaluation for patients seen between January 1, 1997 and October 30, 2004. Survival analysis and Cox proportional hazards modeling were used to describe the time to evaluation and covariates associated with this outcome. Patients were predominantly white and male. Of 248 eligible patients, 108 (44%) were evaluated for HCV treatment. The median time to evaluation was 2.98 years. Of 108 evaluated, 17 (16%) received at least one dose of interferon and/or ribavirin. The median time to treatment after being evaluated was 1.39 years. Of the 17 (35%) treated 6 patients had a sustained virologic response, but only 2.4% of the original number of patients were cured. Approximately one half of patients in an HIV-specialty clinic were evaluated for HCV therapy and 16% received treatment, but the median time to treatment from the time of HCV diagnosis was over 4 years. Further efforts to identify and to overcome barriers to HCV treatment are warranted.